Johnson & Johnson Vision Showcases the Rising Burden of Myopia, New Contact Lens and Surgical Technologies at ARVO

Johnson & Johnson Vision showcased new research abstracts covering topics across a range of eye health needs at the Association for Research in Vision and Ophthalmology annual meeting (ARVO) in Vancouver, Canada, April 28-May 2, 2019. Presentations included the first predictive model for direct health and medical costs associated with myopia and related eye conditions around the world, as well as advanced study models that predict new levels of spectacle independence to evaluate IOL designs.

“At ARVO, we’re unveiling new scientific findings across our current product portfolio – ACUVUE, TECNIS Eyhance IOL and iDESIGN – as well as our new product pipeline that will help eye care professionals better meet the evolving needs of their patients,” Xiao-Yu Song, PhD, MD, Global Head of Research and Development, Johnson & Johnson Vision Care, said in a company news release. “We’re also pioneering health outcomes research in the myopia space so that we can increase understanding of this large-scale issue and continue to work with the eye care professional community and others on new research, treatment, and advocacy strategies.”

Investigational Antihistamine-Releasing Contact Lens & New Technologies

On the heels of phase 3 data published in the journal Cornea for the company’s investigational antihistamine releasing contact lens, Pall B. el al. will present findings from an initial evaluation of efficacy with different doses of the antihistamine ketotifen. (“Clinical Trial Evaluating the Reduction of Itch with a Novel Contact Lens and Antihistamine Combination Product,” B0170 Thursday, May 2, 2019, 10:15 AM – 12:00 PM PT, West Exhibition Hall)

Additional contact lens research of note for presentation include:

• “UV light-blocking contact lenses prevent UVB-induced DNA and oxidative damage of the limbal stem cell niche, protect against inflammation and maintain putative stem cell phenotype,” Notara M. B0468 Sunday, April 28, 2019 1:00 PM – 2:45 PM PT, West Exhibition Hall                                                                                                                            
• “Ocular Comfort observed with RevitaLens Solution at 45 and 120 minutes,” Mingqi Bai B0446 Thursday, May 2, 2019 8:00 AM – 9:45 AM PT, West Exhibition Hall
• “Influence of contact lens material in shielding against atmospheric pollutants,” Popwell B0420 Thursday, May 2, 2019 8:00 AM – 9:45 AM PT, West Exhibition Hall

Cataract & Refractive

Johnson & Johnson Vision is highlighting new data on spectacle independence, visual acuity, and the effect of acrylic material characteristics on stray light performance. Findings on the newly released TECNIS Eyhance^ǂ IOL, in Europe, support preclinical findings that the product provides excellent monocular and binocular 20/20 vision.¹ New data to support pipeline products in the presbyopia-correcting IOL (PCIOL) category will also be revealed.

• Data presented by Rosen et al. provides a model to predict rates of spectacle independence from clinical data to evaluate IOL designs. (“Spectacle independence of pseudophakic patients predicted from preclinical data,” Rosen R. B0261 Tuesday, April 30, 2019 11:45 AM – 1:30 PM PT, West Exhibition Hall)
• Data presented by Weeber et al. provides an analysis of light scatter between hydrophilic and hydrophobic IOL designs, further supporting the TECNIS platform by reinforcing that the TECNIS hydrophobic lens material is not associated with glistenings,^2-6which can inhibit patients’ vision. (“Effect of acrylic material characteristics on stray light performance,” Weeber H. B0251 Tuesday, April 30, 2019 11:45 AM – 1:30 PM PT, West Exhibition Hall)
• A presentation by Alarcon A. et al. concludes that higher-order aspheric IOLs provided an improvement in intermediate simulated visual acuity and maintained distance image quality comparable to that of an aspheric IOL, independent of the pupil size. This data supports the newly released TECNIS Eyhance^ǂ IOL, in Europe, and reinforces that TECNIS Eyhance IOL allows patients to achieve significantly improved intermediate vision, compared with a standard aspheric monofocal IOL.⁷ (“Refractive technology to improve intermediate vision in monofocal intraocular lenses,” Alarcon A. B0260 Tuesday, April 30, 2019 11:45 AM – 1:30 PM PT, West Exhibition Hall)
• Data presented by Canovas et al. provide strong evidence that IOL materials with UV and Violet blocking properties that continue to transmit healthy blue light provide a superior subjective response on several aspects of functional experience and points out to potential reduction in halos when compared to clear lenses with only UV blockers. (“Optical and Visual performance of violet blocking intraocular lenses,” Canovas C. B0264 Tuesday, April 30, 2019 11:45 AM – 1:30 PM PT, West Exhibition Hall)

Additionally, a presentation by Neal D. et al. (“Objective determination of visual acuity from a single wavefront measurement,” Neal D. B0082 Sunday, April 28, 2019 1:00 PM – 2:45 PM PT, West Exhibition Hall), will connect objective measurements of the eye, used for wavefront-guided, data-driven personalized refractive surgery, with visual acuity as a primary subjective measure of ocular performance. This provides further evidence on how the new iDESIGN Refractive Studio System can be used for diagnosis and treatment in refractive surgery. iDESIGN Refractive Studio is the only system to use topography-integrated, wavefront-guided technology⁸ enabling data-driven personalization; this combination allows surgeons to measure and treat better.

Myopia Health Outcomes & Treatment Insights

Three abstracts on myopia point to the need for evidence-based treatment criteria and new solutions to address this growing global health threat.

• In a new, landmark health outcomes analysis, Holy CE et al. project the future human, financial and societal costs from myopia, demonstrating they are significantly underestimated around the world. (“Predicting Costs and Disability from the Myopia Epidemic – A Worldwide Economic and Social Model,” Holy CE. B0357 Wednesday, May 1, 2019 3:00 PM – 4:45 PM PT, West Exhibition Hall)
• In two separate analyses, researchers evaluated current treatment interventions to provide more clarity and evidence-based guidance for interpreting and measuring efficacy in myopia. (“Myopia control intervention produces an absolute, rather than a relative, treatment effect across the progression range,” Brennan N. A0060 Wednesday, May 1, 2019 8:15 AM – 10:00 AM PT, West Exhibition Hall and “Modelling of cumulative treatment efficacy in myopia progression interventions,” Cheng X. A0061 Wednesday, May 1, 8:15 AM – 10:00 AM PT, West Exhibition Hall)

1. Data on File, Johnson & Johnson Surgical Vision, Inc. 2018. DOF2018CT4015.
2. Data on File. Johnson & Johnson Surgical Vision, Inc. 2013.
3. Nagata M, Matsushima H, Mukai K, Terauchi W, Senoo T, Wada H, Yoshida S. Clinical evaluation of the transparency of hydrophobic acrylic intraocular lens optics. J Cataract Refract Surg. 2010;36(12):2056-2060.
   4. Christiansen G, et al. Glistenings in the AcrySof® intraocular lens: Pilot study.J Cataract Refract Surg. 2001;27(5):728-733.
   5. Colin J, et al. Incidence of glistenings with the latest generation of yellow-tinted hydrophobic acrylic intraocular lenses.J Cataract Refract Surg. 2012;38(7):1140-1146.
   6. Gunenc U, et al. Effects on visual function of glistenings and folding marks in AcrySof® intraocular lenses. J Cataract Refract Surg. 2001;27(10):1611-1614.
4. Based on a clinical study, N= 134 achieved mean 20/20 monocular pooled distance BCDVA Data on File, Johnson & Johnson Surgical Vision, Inc. 2018. DOF2018CT4015.
5. iDESIGN Refractive Studio treatment calculations are made using wavefront measurements, and use either measured topography or keratometry for propagating the wavefront and compensating for the cosine effect (peripheral loss of laser energy due to corneal curvature)

^ǂ TECNIS Eyhance IOL has European CE Mark approval and is now commercially available across Europe. This product is not currently approved or commercially available in other countries. The TECNIS Eyehance IOL is not licensed in accordance with Canadian law.